Johnson & Johnson remains a Buy for its stability and consistent dividends, despite short-term price fluctuations and modest ...

In one of the studies, Merck's combination was shown to be safe and "non-inferior" to Gilead Sciences' top-selling ... the health regulator's strictest, to flag the risk of worsening hepatitis ...

The Chargers and Oakley hosted their 2nd Annual Girls Flag Football Invitational Tournament ... with Chargers legend Corey Liuget on hand to support the kids. In partnership with Gilead Sciences, the ...

Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

This was the stock's fourth consecutive day of losses.

The most recent trading session ended with Gilead Sciences (GILD) standing at $91.41, reflecting a -0.51% shift from the previouse trading day's closing. The stock's performance was behind the S&P ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.10% of ...

TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $92.37 which represents a slight increase of $0.36 or 0.39% from the prior close of $92.01. The stock opened at $92.59 and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively ...